Mireca
Protecting eyesight with a small molecule in a broad band of mutations
hero_pattern.png

MIRECA

Preserving eyesight.

 

Developing small molecules to treat a broad band of photoreceptor mutations

Mireca is a pre-clinical stage ophthalmology start-up company seated in Tübingen (Germany) aiming to bring its targeted, small molecule drug candidate to patients suffering from inherited retinal degeneration like Retinitis Pigmentosa, Leber’s congenital amaurosis, and Stargardt’s disease covering a broad range of mutations.

The company creates value through leveraging the combination of orphan size drug development, orphan market protection and a large combined market size protected by its proprietary intellectual property.

 

Latest

➤ Key patent granted

Mireca receives the validating “Notice of Allowance” from the USPTO for its proprietary formulation and medical use patent application “Targeted liposomal delivery of cGMP analogues” (PCT/EP2016/055659).

➤ Meet us At

April 8, 2019 at Biotech Investors Day in Würzburg

April 26 - May 2, 2019 in Vancouver (BC) around ARVO

May 6-7, 2019 invited speaker at French American Innovation Day in Los Angeles